Risks versus benefits in the clinical application of aromatase inhibitors

Endocrine-Related Cancer

Volumn 6, Issue 2, 1999, Pages 325-332

  Goss, P E ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE; AROMATASE INHIBITOR; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; HYDROCORTISONE; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN; TAMOXIFEN CITRATE; VOROZOLE;

ARTICLE; ASTHENIA; BONE METABOLISM; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; DYSPEPSIA; EDEMA; ESTROGEN SYNTHESIS; FATIGUE; HEADACHE; HOT FLUSH; HUMAN; LIPID METABOLISM; NAUSEA; POSTMENOPAUSE; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; VOMITING;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTROGENS; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; RISK;

EID: 0032974362     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0060325     Document Type: Article

References (45)

1. Barrett-Connor E & Bush TL 1991 Estrogen and coronary heart disease in women. Journal of the American Medical Association 265 1861-1867.
2. Bergh J, Bonneterre J, Illiger HJ, Murray R, Nortier J, Paridaens R, Rubens RD, Samonigg H & Van Zyl J, for the Vorozole Study Group 1997 Vorozole (Rivizor) versus aminoglutethimide in the treatment of postmenopausal breast cancer relapsing after tamoxifen [Abstract, No. 543]. Proceedings of the American Society of Oncology 16 155A.
3. Bhatnagar AS, Hausler A, Schieweck K, Lang M & Bowman R 1990 Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor. Journal of Steroid Biochemistry and Molecular Biology 37 1021-1027.
4. Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, Lockwood GA, Tritchler DL & Yaffe MJ 1995 Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. Journal of the National Cancer Institute 87 670-675.
5. Brincat M, Moniz CJ, Studd JW, Darby A, Magos A, Emburey G & Versi E 1985 Long-term effects of the menopause and sex hormones on skin thickness. British Journal of Obstetrics and Gynaecology 92 256-259.
6. Buzdar A, Jonat W, Howell A, Jones SE, Blomqvist C, Vogel CL, Eiermann W, Wolter JM, Azab M, Webster A & Plourde PV, for the Arimidex Study Group 1996 Anastrozole, a potent and selective aromatase inhibitor versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Journal of Clinical Oncology 14 2000-2011.
7. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D & Cummings SR, for the Study of Osteoporotic Fractures Research Group 1995 Estrogen replacement therapy and fractures in older women. Annals of Internal Medicine 122 9-16.
8. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS & Cummings SR for the Osteoporotic Fractures Research Group 1996 Bone mineral density and risk of breast cancer in older women. The study of Osteoporotic fractures. Journal of the American Medical Association 276 1404-1408.
9. Coope J, Thomson JM & Poller L 1975 Effects of 'natural estrogen' replacement therapy on menopausal symptoms and blood clotting. British Medical Journal 4 139-143.
10. Daly E, Gray A, Barlow D, McPherson K, Roche M & Vessey M 1993 Measuring the impact of menopausal symptoms on quality of life. British Medical Journal 307 836-840.
11. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux A-C, Shah AS, Huster WJ, Draper M & Christiansen C 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. New England Journal of Medicine 3371641-1647.
12. Ditkoff EC, Crary WG, Cristo M & Lobo RA 1991 Estrogen improves psychological function in asymptomatic postmenopausal women. Obstetrics and Gynecology 78 991-995.
13. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M, Fornasiero A, Hoffmann W, Michael J, Hatschek T, Tjabbes T, Chaudri HA, Hornberger U & Trunet PF 1998 Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. Journal of Clinical Oncology 16 453-461.
14. Evans TRJ, Di Salle E, Ornati G, Lassus M, Strolin Benedetti M, Pianezzola E & Coombes RC 1992 Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women. Cancer Research 52 5933-5939.
15. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Arkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N & other National Surgical Adjuvant Breast and Bowel Project Investigators 1998 Tamoxifen for prevention of breast cancer. Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute 90 1371-1388.
16. Gambrell RD & Teran AZ 1991 Changes in lipids and lipoproteins with long-term estrogen deficiency and hormone replacement therapy. American Journal of Obstetrics and Gynecology 165 307-317.
17. Gershanovich M, Chaudri HA, Campos D, Lurie H, Bonaventura A, Jeffrey M, Buzzi F, Bodrogi I, Ludwig H, Reichardt P, O'Higgins N, Romieu G, Friederich P & Lassus M, for the Letrozole International Trial Group (AR/BC3) 1998 Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Annals in Oncology 9 639-645.
18. Giudici D, Ornati G, Briatico G, Buzzetti F, Lombardi P & Di Salle E 1988 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. Journal of Steroid Biochemistry 30 391-394.
19. Goss PE, Clark RM, Ambus U, Weizel HAE, Wadden NA, Crump M, Walde D, Tye LM, De Coster R & Bruynseels J 1995 Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen. Clinical Cancer Research 1 287-294.
20. Goss PE, Winer EP, Tannock IF & Schwartz LH on behalf of the North American Vorozole Study Group 1999 A randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. Journal of Clinical Oncology 17 52-63.
21. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL & Cummings SR 1992 Hormone therapy to prevent disease and prolong life in postmenopausal women. Annals of Internal Medicine 117 1016-1037.
22. Henderson BE 1989 The cancer question: an overview of recent epidemiologic and retrospective data. American Journal of Obstetrics and Gynecology 161 1859-1864.
23. Henderson IC 1991 Endocrine therapy in metastatic breast cancer. In Breast Diseases, edn 2, pp 419-422. Eds JR Harris, S Hellman, IC Henderson et al. Philadelphia, PA, USA: Lippincott.
24. Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF & Dowsett M 1993 Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Research 53 266-270.
25. Jones S, Vogel C, Fehrenbacher L, Eisenberg P, Cooper B, Honig S, Arkhipov A, Tiffany J, Polli A, Whaley F, di Salle E, Consonni A & Miller L, for the Exemestance Study Group 1998 Antitumor efficacy of exemestane (Nikidess) as third-line hormonal therapy in the treatment of postmenopausal women with metastatic breast cancer refractory to tamoxifen and Megace [Abstract, No. 573]. Proceedings of the American Society of Clinical Oncology 17 150A.
26. Limouzin-Lamothe M-A, Mairon N, Joyce CRB & Le Gal M 1994 Quality of life after the menopause: influence of hormonal replacement therapy. American Journal of Obstetrics and Gynecology 170 618-624.
27. Lobo RA 1991 Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 73 925-931.
28. Lonning PE, Paridaens R, Thurlimann B, Piscitelli G & di Salle E 1997 Exemestane experience in breast cancer treatment. Journal of Steroid Biochemistry and Molecular Biology 61 151-155.
29. McHorney CA, Ware JJ & Raczek AE 1993 The MOS 36-Item Short-Form Health Survey (SF-36) II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care 31 247-263.
30. Nease RF Jr & Ross JM 1995 The decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in healthy women: an analysis of the tradeoffs. American Journal of Medicine 99 180-189.
31. Nilas L & Christiansen C 1987 Bone mass and its relationship to age and the menopause. Journal of Clinical Endocrinology and Metabolism 65 696-702.
32. Palinkas LA & Barrett-Connor E 1992 Estrogen use and depressive symptoms in postmenopausal women. Obstetrics and Gynecology 80 30-36.
33. Plourde PV, Dyroff M & Dukes M 1994 Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Treatment and Research 30 103-111.
34. Saftlas AF & Szklo M 1987 Mammographic parenchymal patterns and breast cancer risk. Epidemiology Reviews 9 146-174.
35. Sherwin BB 1994 Estrogenic effects on memory in women. Annals of the New York Academy of Sciences 743 213-231.
36. Sherwin BB & Tulandi T 1996 'Add-back' estrogen reverses cognitive deficits induced by gonadotropin-releasing hormone agonist in women with leiomyomata uteri. Journal of Clinical Endocrinology and Metabolism 81 2545-2549.
37. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE & Hennekens CH 1991 Postmenopausal estrogen therapy and cardiovascular disease. New England Journal of Medicine 325 756-762.
38. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS & Wang DY 1997a A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. British Journal of Cancer 75 1075-1079.
39. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS & Wang DY 1997b A prospective study of endogenous serum hormone concentrations and breast cancer risk in postmenopausal women on the island of Guernsey. British Journal of Cancer 76 401-405.
40. Vanderschueren D, van Herck E, Nijs J, Ederveen AG, De Coster R & Bouillon R 1997 Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats. Endocrinology 138 2301-2307.
41. Wessler S 1992 Estrogen-associated thromboembolism. Annals ofEpidemiology 2 439-443.
42. Whitehead MI, Townsend PT, Pryse-Davies J, Ryder TA & King RJ 1981 Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. New England Journal of Medicine 305 1599-1605.
43. Wolfe JN 1976 Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer 37 2486-2492.
44. Wouters W, Van Ginckel R, Krekels M, Bowden C & De Coster R 1993 Pharmacology of vorozole. Journal of Steroid Biochemistry and Molecular Biology 44 617-621.
45. Zhang Y, Kiel DP, Kreger BE, Cupples LA, Ellison RC, Dorgan JF, Schatzkin A, Levy D & Felson DT 1997 Bone mass and the risk of breast cancer among postmenopausal women. New England Journal of Medicine 336 611-617.